The same class of carrier that delivered billions of mRNA vaccine doses. Lipids mimic the cell membrane, so they can wrap fragile nucleic acids, slip into cells and let the cargo out where it is needed.
- Typical size
- 50–150 nm
- Cargo
- DNA, mRNA, siRNA, CRISPR
- Clinical status
- Approved medicines
Gene delivery underpins modern molecular medicine, from gene therapy to vaccines. Of all the ways to carry genetic material into cells, lipid-based reagents have become the most widely adopted and versatile. The family spans cationic lipids, liposomes and lipid nanoparticles (LNPs), all of which borrow the natural biocompatibility and membrane-like behaviour of lipids.
Decades of chemistry culminated in approved medicines: the Pfizer–BioNTech and Moderna COVID-19 vaccines, and patisiran, the first approved siRNA drug, for hereditary transthyretin amyloidosis. The same carriers are now being developed for cancer immunotherapy, protein replacement and CRISPR gene editing.
Their strength lies in size and surface chemistry. Small, tunable particles can navigate biological barriers, enter cells by endocytosis and, critically, release their cargo into the cytoplasm by disrupting the endosomal membrane from inside.
Inside a lipid nanoparticle
Ionisable lipid
Neutral in the blood, which lowers toxicity, but positively charged in the acidic endosome, where it binds the cargo and drives escape.
Phospholipid
A helper lipid such as DSPC or DOPE that supports the particle structure and encourages membrane fusion.
Cholesterol
Fills the gaps between lipids, stabilising the particle and improving packing efficiency.
PEG-lipid
Forms a water-loving outer layer that stops particles clumping and slows clearance by the immune system.
How it works
- 1
Self-assembly
Lipids in ethanol meet nucleic acid in acidic buffer in a microfluidic mixer and close around the cargo in milliseconds.
- 2
Circulation and uptake
Near-neutral, PEG-coated particles circulate quietly, then enter cells by endocytosis.
- 3
Endosomal escape
As the endosome acidifies, the ionisable lipid becomes positively charged and disrupts the endosomal membrane.
- 4
Release and action
The cargo reaches the cytoplasm, where mRNA is translated into protein or siRNA silences its target gene.
Four generations of lipid reagent
Lipid reagents are grouped by chemical structure and how they work.
| Type | What it is | Best for |
|---|---|---|
| Cationic lipids | Permanently charged lipids such as DOTAP or DOTMA that bind nucleic acids strongly | DNA transfection in easy-to-transfect cell lines |
| Cationic liposomes | Vesicles of cationic lipid plus a neutral helper lipid such as DOPE, for better fusion and stability | General-purpose transfection, siRNA |
| Ionisable lipids | Neutral at physiological pH, charged only in acidic endosomes, so less toxic in vivo | mRNA, CRISPR RNP, in vivo work |
| Lipid nanoparticles | Ionisable lipid, phospholipid, cholesterol and PEG-lipid in one engineered particle | Therapeutics and vaccines |
How lipids compare with other methods
| Feature | Lipid-based | Polymer (PEI) | Electroporation | Viral vectors |
|---|---|---|---|---|
| Efficiency | High | High | Very high | Very high |
| Ease of use | Very easy | Easy | Moderate | Complex |
| Toxicity | Low–moderate | Moderate–high | High | Low |
| In vivo use | Good with LNPs | Limited | Limited | High |
| Cargo capacity | High (10+ kb plasmids) | High | High | Limited |
| Expression | Transient | Transient | Transient or stable | Stable |
| Cost | Moderate–high | Low | Medium (device) | Very high |
Strengths
- High efficiency. Excellent transfection rates in many adherent and suspension cell lines.
- Broad compatibility. Works in HEK293, HeLa, CHO and some primary cells.
- Simple protocol. Mix reagent with nucleic acid and add to cells, with no special equipment.
- Low toxicity. Modern ionisable formulations keep cell viability high.
- One platform, many cargoes. DNA, mRNA, siRNA, miRNA and CRISPR components in the same system.
- Proven in the clinic. Regulatory precedent and manufacturing at global scale.
Challenges
- Liver bias. After systemic injection, LNPs collect mainly in the liver, limiting other organs.
- Immune activation. Some lipids and PEG can trigger immune or inflammatory responses.
- Storage. Many formulations need cold-chain or frozen storage to stay stable.
- Endosomal escape. Only a small fraction of the cargo actually reaches the cytoplasm.
- Transient expression. Expression typically lasts 24–96 hours, so long studies need selection or redosing.
- Cell-type variability. Primary cells and neurons often need optimisation or specialised reagents.
Where it is used
mRNA vaccines
Deliver mRNA that instructs cells to make an antigen and train the immune system.
Gene silencing
siRNA therapeutics such as patisiran knock down disease-causing proteins.
Protein replacement
mRNA supplies a missing or faulty enzyme for a limited time.
Gene editing
Cas9 mRNA and guide RNA delivered together for in vivo CRISPR editing.
Cancer immunotherapy
mRNA encoding tumour antigens or immune-stimulating proteins.
Research and bioproduction
Routine transfection, from small experiments to large-scale protein production.
What comes next
The next challenge is reaching beyond the liver. New lipid designs aim to make delivery more selective, safer and easier to manufacture.
Tissue-targeting ligands
Antibodies, peptides or sugars on the surface steer particles to specific cells.
Stimuli-responsive lipids
Lipids that change charge or shape in acidic tumours or inflamed tissue.
Organ-selective formulations
Tuned composition to deliver to the lungs, spleen, brain or tumours.
Scalable manufacturing
Continuous-flow production to cut batch-to-batch variability under GMP.
Lipid nanoparticles bridge the gap between the promise of genetic medicines and their clinical reality, and they keep evolving through chemistry, nanotechnology and molecular biology.